Medicinal Product Shortages - update - 31 August 2022

Notice type: Advisory

Date: 31/08/2022


Further Information:

 The Health Products Regulatory Authority has been notified of a shortage of the following products:

  • Artelac 3.2 mg/ml Eye Drops, Solution - PA23259/004/001
  • Ceftazidime 2g Powder for Solution for Injection or Infusion - PA0281/224/002
  • Concerta XL 18mg Prolonged-Release Tablets - PA22612/002/001
  • DuoPlavin 75mg/75mg Film-Coated Tablets - EU/1/10/619/002
  • Dynastat 40mg Powder for Solution for Injection - EU/1/02/209/005
  • Gamanil 70mg Film-Coated Tablets - PA1701/004/001
  • Macrolief 13.8g sachet, Powder for Oral olution - PA0711/224/001
  • Minocin SA 100mg Modified Release Capsules - PA2010/060/001
  • Nebilet Plus 5mg/25mg Film-Coated Tablets - PA0865/015/002
  • Noxafil 40mg/ml Oral Suspension - EU/1/05/320/001
  • Palladone SR 2mg Prolonged Release Capsules - PA1688/007/007
  • Provera 10mg Tablets - PA0822/134/003
  • Taxotere 20mg/1ml Concentrate for Solution for Infusion - EU/1/95/002/003
  • Toviaz 4mg Prolonged Release Tablet - EU/1/07/386/003
  • Vidisic Preservative Free Single Dose Unit - PA23259/008/002
  • Xymel 50mg Capsules - PA0126/099/001


The following shortages have been resolved and supply has resumed to the Irish market:

  • Acerycal 10mg/10mg Tablets - Acerycal 10mg/10mg tablets
  • Calvepen 333mg Tablets - PA0126/137/001
  • Cozaar Comp 100mg/25mg Film Coated Tablets - PA23198/001/003
  • Deslor 0.5mg/ml Oral Solution - PA0711/202/002
  • Doxatan XL 4mg Prolonged Release Tablets - PA0126/202/004
  • Fentanyl 50mcg/ml Solution for Injection (2ml presentation only) - PA2165/011/001
  • Fucidin 20mg/g Cream - PA0046/004/012
  • Loniten 5mg Tablets - PA0822/130/001
  • MST Continus 5mg Prolonged Release Tablets - PA1688/004/001
  • Palladone SR 8mg Prolonged Release Capsules - PA1688/007/009


Please see the shortages section of the HPRA website for further information

The HPRA sends weekly updates concerning medicinal product shortages. However, the above webpage will be updated as new information is provided to the HPRA.

« Back